(TAK) Takeda Pharmaceutical - NYSE
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 49.291m USD | Total Return: 8.6% in 12m
Avg Turnover: 55.1M
EPS Trend: 56.5%
Rev. Trend: 80.4%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Takeda Pharmaceutical Company Limited is a global, research-based biopharmaceutical firm headquartered in Tokyo, Japan. Founded in 1781, the company focuses on six primary therapeutic areas: gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience, and immunology. Its business model relies on a combination of internal R&D, extensive out-licensing, and strategic collaborations with academic institutions and biotechnology firms to maintain a diverse pipeline of branded treatments.
The pharmaceutical sector is characterized by high capital expenditures and long product development lifecycles, often exceeding a decade from discovery to market. Takeda manages these risks through a global distribution network and a portfolio of established brands such as Entyvio and Vyvanse. Investors can further evaluate the companys long-term valuation metrics and growth drivers on ValueRay.
As a global entity, Takeda operates through integrated manufacturing and marketing segments across international markets. This geographic diversification helps mitigate local regulatory risks and patent expiration impacts common in the large-cap pharmaceutical industry.
- Entyvio sales growth sustains revenue amid competitive pressures in gastroenterology market
- Plasma-derived therapy expansion drives long-term margin improvements and volume growth
- Vyvanse patent expiration creates significant revenue headwinds and generic competition risks
- R&D pipeline execution determines replacement of legacy drug revenue losses
- Yen volatility significantly impacts reported earnings and international debt servicing costs
| Net Income: 193b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -1.13 > 1.0 |
| NWC/Revenue: 14.60% < 20% (prev 0.32%; Δ 14.28% < -1%) |
| CFO/TA 0.06 > 3% & CFO 973b > Net Income 193b |
| Net Debt (4305b) to EBITDA (1427b): 3.02 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.12b) vs 12m ago -1.21% < -2% |
| Gross Margin: 58.47% > 18% (prev 65.51%; Δ -7.04% > 0.5%) |
| Asset Turnover: 30.55% > 50% (prev 32.15%; Δ -1.60% > 0%) |
| Interest Coverage Ratio: 1.88 > 6 (EBIT TTM 679b / Interest Expense TTM 361b) |
| A: 0.04 (Total Current Assets 3104b - Total Current Liabilities 2440b) / Total Assets 15520b |
| B: 0.07 (Retained Earnings 1061b / Total Assets 15520b) |
| C: 0.05 (EBIT TTM 679b / Avg Total Assets 14884b) |
| D: 1.01 (Book Value of Equity 7807b / Total Liabilities 7712b) |
| Altman-Z'' = 1.87 = BBB |
| DSRI: 1.22 (Receivables 880b/725b, Revenue 4547b/4582b) |
| GMI: 1.12 (GM 65.51% / 58.47%) |
| AQI: 0.97 (AQ_t 0.66 / AQ_t-1 0.68) |
| SGI: 0.99 (Revenue 4547b / 4582b) |
| TATA: -0.05 (NI 193b - CFO 973b) / TA 15520b) |
| Beneish M = -2.76 (Cap -4..+1) = A |
As of June 10, 2026, the stock is trading at USD 15.72 with a total of 4,569,416 shares traded.
Over the past week, the price has changed by +3.56%,
over one month by -3.91%,
over three months by -11.56% and
over the past year by +8.58%.
Takeda Pharmaceutical has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy TAK.
- StrongBuy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 20.4 | 29.7% |
P/E Trailing = 42.1622
P/E Forward = 9.8814
P/S = 0.0109
P/B = 1.0047
P/EG = 0.3891
Revenue TTM = 4547b USD
EBIT TTM = 679b USD
EBITDA TTM = 1427b USD
Long Term Debt = 4270b USD (from longTermDebt, two quarters ago)
Short Term Debt = 514b USD (from shortTermDebt, last quarter)
Debt = 4903b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4305b USD (calculated: Debt 4903b - CCE 598b)
Enterprise Value = 4355b USD (49.3b + Debt 4903b - CCE 598b)
Interest Coverage Ratio = 1.88 (Ebit TTM 679b / Interest Expense TTM 361b)
EV/FCF = 5.75x (Enterprise Value 4355b / FCF TTM 757b)
FCF Yield = 17.39% (FCF TTM 757b / Enterprise Value 4355b)
FCF Margin = 16.65% (FCF TTM 757b / Revenue TTM 4547b)
Net Margin = 4.25% (Net Income TTM 193b / Revenue TTM 4547b)
Gross Margin = 58.47% ((Revenue TTM 4547b - Cost of Revenue TTM 1888b) / Revenue TTM)
Gross Margin QoQ = 48.79% (prev 54.43%)
Tobins Q-Ratio = 0.28 (Enterprise Value 4355b / Total Assets 15520b)
Interest Expense / Debt = 7.35% (Interest Expense 361b / Debt 4903b)
Taxrate = 26.06% (68.2b / 262b)
NOPAT = 502b (EBIT 679b * (1 - 26.06%))
Current Ratio = 1.27 (Total Current Assets 3104b / Total Current Liabilities 2440b)
Debt / Equity = 0.63 (Debt 4903b / totalStockholderEquity, last quarter 7807b)
Debt / EBITDA = 3.02 (Net Debt 4305b / EBITDA 1427b)
Debt / FCF = 5.69 (Net Debt 4305b / FCF TTM 757b)
Total Stockholder Equity = 7363b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.30% (Net Income 193b / Total Assets 15520b)
RoE = 2.62% (Net Income TTM 193b / Total Stockholder Equity 7363b)
RoCE = 5.83% (EBIT 679b / Capital Employed (Equity 7363b + L.T.Debt 4270b))
RoIC = 3.75% (NOPAT 502b / Invested Capital 13367b)
WACC = 5.44% (E(49.3b)/V(4952b) * Re(5.82%) + D(4903b)/V(4952b) * Rd(7.35%) * (1-Tc(0.26)))
Discount Rate = 5.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -15.56 | Cagr: -0.64%
[DCF] Terminal Value 73.70% ; FCFF base≈797b ; Y1≈722b ; Y5≈623b
[DCF] Fair Price = 1.78k (EV 9921b - Net Debt 4305b = Equity 5615b / Shares 3.16b; r=8.35% [WACC [floored]]; 5y FCF grow -11.58% → 2.50% )
EPS Correlation: 56.53 | EPS CAGR: 67.26% | SUE: N/A | # QB: 0
Revenue Correlation: 80.42 | Revenue CAGR: 3.65% | SUE: 0.16 | # QB: 0
EPS current Year (2027-03-31): EPS=94.98 | Chg30d=-22.29% | Revisions=-20% | GrowthEPS=+55.7% | GrowthRev=+680.8%